Active Ingredient History

  • Now
Methazolamide is topical carbonic anhydrase inhibitor. Methazolamide is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. Methazolamide is a sulfonamide derivative; however, it does not have any clinically significant antimicrobial properties. Although methazolamide achieves a high concentration in the cerebrospinal fluid, it is not-considered an effective anticonvulsant. Methazolamide has a weak and transient diuretic effect, therefore use results in an increase in urinary volume, with excretion of sodium, potassium and chloride. Methazolamide is a potent inhibitor of carbonic anhydrase. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Methazolamide is used for treatment of chronic open-angle glaucoma and acute angle-closure glaucoma.   NCATS

  • SMILES: CN1N=C(S\C1=N\C(C)=O)S(N)(=O)=O
  • Mol. Mass: 236.272
  • ALogP: -1.42
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$0.6601 - $3.7886
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

metazolamida | metazolamide | methazolamid | methazolamide | méthazolamide | methazolamidum | methenamide | neptazane | neptazaneat | n-methylacetazolamide


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue